A*STAR Infectious Diseases Labs (A*STAR IDL)

A profile of the immune responses from Singaporean patients recovered from COVID-19 has revealed an urgent need to update vaccines against new viral variants.

Remdesivir treatment is more likely to be successful in COVID-19 patients who are naturally able to mount a strong immune response against infections.

A*STAR researchers create a next-generation, ultrasensitive COVID-19 rapid test powered by gold nanoparticles.